InflaRx (IFRX) CFO details extensive stock option and share holdings
Rhea-AI Filing Summary
InflaRx N.V. Chief Financial Officer Thomas Taapken has filed an initial Form 3 detailing his equity holdings in the company. The filing shows indirect ownership, through tomtaa GmbH, of multiple stock option grants over Ordinary Shares with exercise prices generally around 1.86–2.44 and staggered expirations from 2030 to 2036. One grant covers 240,000 options expiring in 2036 and another 210,000 expiring in 2034. A separate performance stock option for 72,000 shares vests based on a financing event and the average Ordinary Share price in quarter four of 2026 exceeding $1.50. Taapken also directly holds 3,500 Ordinary Shares. Several option grants are already fully vested and exercisable, while the January 2026 grant vests in four equal quarterly installments, all subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (11)
- F1. This option was granted on September 18, 2020 and is fully vested and exercisable as of the date hereof.
- F2. The reported securities are directly held by tomtaa GmbH, a company wholly owned by the Reporting Person for which the Reporting Person acts as sole managing director. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
- F3. This option was granted on January 4, 2021 and is fully vested and exercisable as of the date hereof.
- F4. This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof.
- F5. This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof.
- F6. This option was granted on November 21, 2022 and is fully vested and exercisable as of the date hereof.
- F7. This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.
- F8. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.
- F9. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.
- F10. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 60,000 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.
- F11. This option shall vest depending upon achievement of the following performance criteria: (i) 50% shall vest if a certain financing event takes place before the fourth quarter of 2026 and (ii) 50% shall vest if the average Ordinary Share price for quarter four of 2026 exceeds $1.50.
AI-generated analysis. How Rhea-AI works. Not financial advice.
